

Moderna, Inc.  
Form SC 13G  
January 30, 2019

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**SCHEDULE 13G**

**Under the Securities Exchange Act of 1934  
(Amendment No. )\***

**Moderna, Inc.**

(Name of Issuer)

**Common Stock, par value \$0.0001 per share**

(Title of Class of Securities)

**60770K107**

(CUSIP Number)

**December 6, 2018**

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- Rule 13d-1(b)
- Rule 13d-1(c)
- Rule 13d-1(d)

\*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 ( Act ) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Edgar Filing: Moderna, Inc. - Form SC 13G

CUSIP No. 60770K107

- |     |  |  |
|-----|--|--|
| 1.  | Name of Reporting Person<br>AstraZeneca PLC  |  |
| 2.  | Check the Appropriate Box if a Member of a Group (See Instructions)                  |  |
|     | (a) <input type="radio"/>  |  |
|     | (b) <input checked="" type="checkbox"/>  | x (Joint filers)                               |
| 3.  | SEC Use Only   |  |
| 4.  | Citizenship or Place of Organization<br>United Kingdom                               |  |
| 5.  |  | Sole Voting Power<br>25,499,325 shares(1)      |
| 6.  |  | Shared Voting Power<br>0 shares                |
| 7.  |  | Sole Dispositive Power<br>25,499,325 shares(2) |
| 8.  |  | Shared Dispositive Power<br>0 shares           |
| 9.  | Aggregate Amount Beneficially Owned by Each Reporting Person<br>25,499,325 shares(3) |  |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  | <input type="radio"/>                          |
| 11. | Percent of Class Represented by Amount in Row (9)<br>7.75%(4)                        |  |
| 12. | Type of Reporting Person (See Instructions)<br>CO                                    |  |

---

(1) Represents shares directly held by Zeneca Inc., a wholly-owned subsidiary of AstraZeneca PLC. AstraZeneca PLC and Zeneca Inc. may each be deemed to have sole voting and dispositive power over the shares.

(2) See footnote 1.

(3) See footnote 1.

(4) The percentage ownership was calculated based on 328,948,088 shares of the issuer's common stock outstanding as of December 11, 2018, upon closing of the issuer's initial public offering, as reported in the issuer's prospectus dated December 6, 2018 (the Final Prospectus) filed with the Securities and Exchange Commission (the SEC) on December 7, 2018 pursuant to Rule 424(b)(4) under the Securities Act of 1933, as amended (the Securities Act).

Edgar Filing: Moderna, Inc. - Form SC 13G

CUSIP No. 60770K107

1. Name of Reporting Person  
Zeneca Inc.
2. Check the Appropriate Box if a Member of a Group (See Instructions)  
(a)  o  
(b)  x (Joint filers)
3. SEC Use Only
4. Citizenship or Place of Organization  
Delaware
- |   |    |  |
|---|----|--|
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person With | 5. | Sole Voting Power<br>25,499,325 shares(5)      |
|   | 6. | Shared Voting Power<br>0 shares                |
|   | 7. | Sole Dispositive Power<br>25,499,325 shares(6) |
|   | 8. | Shared Dispositive Power<br>0 shares           |
9. Aggregate Amount Beneficially Owned by Each Reporting Person  
25,499,325 shares(7)
10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  o
11. Percent of Class Represented by Amount in Row (9)  
7.75%(8)
12. Type of Reporting Person (See Instructions)  
CO

---

(5) See footnote 1.

(6) See footnote 1.

(7) See footnote 1.

(8) See footnote 4.

Edgar Filing: Moderna, Inc. - Form SC 13G

**Item 1.**

- (a) Name of Issuer  
Moderna, Inc.
- (b) Address of Issuer's Principal Executive Offices  
200 Technology Square  
  
Cambridge, MA 02139

**Item 2.**

- (a) Name of Person Filing  
See response to 2(c)
- (b) Address of Principal Business Office or, if none, Residence  
See response to 2(c)
- (c) Citizenship  
This statement is filed on behalf of:

AstraZeneca PLC

1 Francis Crick Avenue

Cambridge Biomedical Campus

Cambridge CB2 0AA

United Kingdom

Citizenship: United Kingdom

Zeneca Inc.

1800 Concord Pike

Wilmington, Delaware, 19803

Citizenship: Delaware

- (d) Title of Class of Securities  
Common Stock, par value \$0.0001 per share
- (e) CUSIP Number  
60770K107

**Item 3.**

**If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:**

- (a)  Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
- (b)  Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
- (c)  Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
- (d)  Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
- (e)  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
- (f)  An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
- (g)  A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
- (h)  A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

Edgar Filing: Moderna, Inc. - Form SC 13G

- (i)           o           A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
- (j)           o           A non-U.S. institution in accordance with § 240.13d 1(b)(1)(ii)(J); Group, in accordance with § 240.13d 1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with
- (k)           o           § 240.13d 1(b)(1)(ii)(J), please specify the type of institution: \_\_\_\_\_

**Item 4. Ownership**

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

(a) Amount beneficially owned:

25,499,325 shares

(b) Percent of class:

7.75%. The percentage stated herein is based on 328,948,088 shares of the issuer's common stock outstanding as of December 11, 2018, upon closing of the issuer's initial public offering, as reported in the Final Prospectus filed with the SEC on December 7, 2018 pursuant to Rule 424(b)(4) under the Securities Act.

(c) Number of shares as to which the person has:

(i) Sole power to vote or to direct the vote:

AstraZeneca PLC: 25,499,325 shares

(ii)

Zeneca Inc.: 25,499,325 shares

Shared power to vote or to direct the vote:

AstraZeneca PLC: 0 shares

(iii)

Zeneca Inc.: 0 shares

Sole power to dispose or to direct the disposition of:

AstraZeneca PLC: 25,499,325 shares

(iv)

Zeneca Inc.: 25,499,325 shares

Shared power to dispose or to direct the disposition of:

AstraZeneca PLC: 0 shares

Zeneca Inc.: 0 shares

Zeneca Inc., a wholly owned subsidiary of AstraZeneca PLC, is the direct record holder of all 25,499,325 shares reported herein. Each of Zeneca Inc. and AstraZeneca PLC may be deemed to have sole voting and dispositive power with respect to such shares.

**Item 5. Ownership of Five Percent or Less of a Class**

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following.

**Item 6. Ownership of More than Five Percent on Behalf of Another Person**

Not applicable.

**Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person**

Not applicable.

**Item 8. Identification and Classification of Members of the Group**

Not applicable.

**Item 9. Notice of Dissolution of Group**

Not applicable.



**Item 10.**  
Not applicable.

**Certifications**

**Material Filed as Exhibits**

**Exhibit 99**                      Joint Filing Agreement between AstraZeneca PLC and Zeneca Inc.

**Signatures**

After reasonable inquiry and to the best of the knowledge and belief of each of the undersigned, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

January 30, 2019

AstraZeneca PLC

/s/ Adrian Kemp

Signature

Adrian Kemp, Company Secretary

Name/Title

Zeneca Inc.

/s/ David E. White

Signature

David E. White, Director and Treasurer

Name/Title

**ATTENTION:**  
**Intentional misstatements or omissions of fact constitute Federal Criminal Violations (See 18 U.S.C. 1001).**